The Iran situation is the one to watch this week. Trump met his national security team on Friday to make what the White House called a “final determination” on next steps, but no deal was announced. Officials had confirmed a framework agreement exists, yet Tehran insists nothing is finalised. Hegseth simultaneously warned the US is ready to restart strikes. The gap between those two positions is wide enough that any resolution — or breakdown — could move oil materially when markets open Monday.

On US-China, Hegseth said bilateral relations are “better than in years,” while still pressing allies to increase defence spending to counter Beijing’s military build-up. The framing is notable: the Pentagon is running both a diplomatic warm-up and a burden-sharing push at the same time. For European defence names, that pressure isn’t going away regardless of how the Iran track resolves.

The proposed changes to US federal research grant rules are worth flagging for anyone with exposure to biotech or university-linked IP. Under the draft framework, peer review becomes optional and political staff would screen grants for prohibited topics, with cancellation possible at any time. If implemented, it would represent a structural shift in how early-stage science gets funded in the US — with downstream consequences for the pipeline that feeds listed biotech.

Ukraine’s use of AI-guided drones to strike Russian supply convoys has been verified by BBC Verify through video analysis. The operational detail matters less than the signal: autonomous targeting of logistics infrastructure is now documented and repeatable. That has implications for how defence procurement conversations develop in NATO capitals over the coming months.

SpaceX has been awarded $6.45 billion in Space Force contracts, disclosed alongside its IPO filing, which also revealed government work accounted for roughly a fifth of 2025 revenue. The contract haul both de-risks the IPO narrative and raises the question of what happens to that revenue stream if the political relationship between Musk and the administration deteriorates further.

A genomics trial published this week suggests millions of breast cancer patients could safely skip chemotherapy based on a low score on a genomic test, with near-identical outcomes using hormone therapy alone. The trial is described as potentially transforming treatment guidelines worldwide. Watch for implications across oncology-focused pharma and diagnostics names.

BP’s turnaround story got a messier backdrop this week, with the FT profiling incoming CEO Meg O’Neill against the backdrop of the “bullying” scandal that removed chair Albert Manifold. The piece lands at a sensitive moment for a stock that has been trying to rebuild institutional confidence.

Monday brings no major UK data release, but Federal Reserve Governor Christopher Waller is scheduled to speak on the economic outlook — worth watching given the current debate about the timing of US rate cuts.

Sources

Al Jazeera, FT, Guardian, BBC News, TechCrunch, Ars Technica, Politico, The Economist — 2026-05-30